Novartis described how its R&D organization uses artificial intelligence in pharmaceutical development to help bring medicines to patients faster.
Healthcare & Life Sciences · Switzerland
Previously: Novartis reported second-quarter 2026 net sales of USD 14.4 billion, up 3%, and reaffirmed full-year 2026 guidance for low-single-digit net-sales growth and a low-single-digit decline in core operating income. It also reported USD 2.8 billion of share repurchases during the first half of 2026.
Read maintained: 2026-10-07